Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study

Last updated: May 16, 2025
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Overall Status: Completed

Phase

N/A

Condition

Lung Injury

Respiratory Failure

Acute Respiratory Distress Syndrome (Ards)

Treatment

PAV+ ventilation strategy

PSV ventilation strategy

Clinical Study ID

NCT02447692
IPR-327433, ISR-2014-10481
  • Ages > 18
  • All Genders

Study Summary

For adult patients with acute respiratory failure requiring invasive mechanical ventilation, does a ventilation strategy using proportional assist ventilation with load-adjustable gain factors (PAV+) result in a shorter duration of time spent on mechanical ventilation than a ventilation strategy using pressure support ventilation (PSV)?

Eligibility Criteria

Inclusion

A staged enrolment process will be used to identify patients eligible to be enrolled and randomized in the study. At each stage of the enrolment process, a patient must meet inclusion criteria and not meet exclusion criteria in order to pass. To progress to the next stage, patients must continue to pass criteria from the prior stages. After enrolment, there are also specific tests to perform (with pass/fail criteria) to determine eligibility to be randomized.

A. SCREENING INCLUSION CRITERIA:

  • A1. Age 18 years or older

  • A2. Intubated and receiving any mode of invasive mechanical ventilation ≥ 24 hours

Exclusion

A. SCREENING EXCLUSION CRITERIA:

  • A3. Anticipating withdrawal of life support and/or shift to palliation as the goalof care

  • A4. Severe central neurologic disorder (eg. Hemorrhage, stroke, tumour) causingelevated intracranial pressure, or impaired control of breathing, or requiringspecific ventilator adjustments (i.e. To attain specific CO2 target) or requiringneurosurgical intervention

  • A5. Known or suspected severe or progressive neuromuscular disorder likely to resultin prolonged or chronic ventilator dependence (eg. Guillain-Barré syndrome,Myasthenia Gravis, ALS, MS, high spinal cord injury, kyphoscoliosis or otherrestrictive disorder) (Note that obesity hypoventilation syndrome that may bemanaged with nocturnal non-invasive ventilation is NOT an exclusion under A5)

  • A6. Severe COPD: Baseline daytime hypercapnia (pCO2> 50 mmHg) OR GOLD 4 airflowlimitation (FEV1<30% predicted) OR MRC class 4 symptoms ("I am too breathless toleave the house" OR "I am breathless when dressing")

  • A7. Broncho-pleural fistula

  • A8. Tracheostomy present at ICU admission for the purpose of chronic or prolongedmechanical ventilation (>21 days). (Note that a patient who was endotracheallyintubated for acute respiratory failure and received a tracheostomy during their ICUadmission, prior to enrolment, is not excluded under A8).

  • A9. Current enrolment in a confounding study, as assessed by the steering committee

  • A10. Previous randomization in the PROMIZING Study

  • A11. Severe, end-stage, irreversible respiratory or cardiac disease (e.g.interstitial lung disease, pulmonary fibrosis, cardiomyopathy, valvulopathy) likelyto result in prolonged or chronic ventilator dependence /unlikely to wean frommechanical ventilation [Note: patients who are candidates for intervention to treatthe underlying respiratory/cardiac disease (e.g. lung transplant, heart transplant,cardiac surgery) may be re-evaluated once intervention is complete and they nolonger meet criteria A11.]

B. ENROLMENT INCLUSION CRITERIA:

  • B1. Ability or potential ability to trigger ventilator breaths (i.e. not receivingneuromuscular blockade).

  • B2. On Assist/Control volume-cycled ventilation: Technically satisfactory plateaupressure ≤ 30 cm H2O (see Operations Manual) OR On Assist/Controlpressure-controlled ventilation or similar mode: Pressure control plus PEEP ≤ 30 cmH2O OR On Pressure Support ventilation: Pressure support plus PEEP ≤ 30 cm H2O OR OnProportional Assist ventilation: PAV gain <85%

  • B3. PaO2 ≥ 60 mmHg or SpO2 ≥ 90% on FiO2 ≤ 0.60 and PEEP ≤ 15 cm H2O

  • B4. Metabolic disorders corrected: pH ≥7.32

  • B5. Stable hemodynamic status: stable or decreasing doses of vasopressors for ≥6hours

  • B6. Anticipate ongoing need for ventilation >24 hours

B. ENROLMENT EXCLUSION CRITERIA:

  • B7. Extubated

  • B8. Died

  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressuresupport of 0-20 cm H2O or proportional assist ventilation of 0-85% for ≥24consecutive hours (including time on CPAP, t-piece, or tracheostomy mask). (Note (1): that it is acceptable to include a patient who has been tried on pressuresupport or proportional assist ventilation but has required pressures >20 cmH2O orassistance >85% or has required return to A/C ventilation within the 24 hour timewindow; Note (2): B9 does not apply to patients on ECMO.)

  • B10. Patient transferred to a non-participating centre

B. ENROLMENT DEFERRAL CRITERIA:

  • B11. Plan to extubate/discontinue mechanical ventilation within <24 hours (Reassesswithin 24 hours)

  • B12. Patient currently on ECMO (Reassess patient once off ECMO)

  • C9: Plan for surgery or complex procedure that will require full ventilation to bedone prior to attempting extubation (e.g. Procedure requiring neuromuscular blockadeand/or heavy sedation, such that patient would be apneic, or not be able to triggerventilator) (Reassess after surgery/procedure complete)

C. PRESSURE SUPPORT TRIAL INCLUSION CRITEIRA:

  • C2. Upon review of Screening and Enrolment criteria (A and B), the patient stillpasses.

  • C3. Treating physician has provided verbal consent to proceed with standardizedtests and randomization if eligibility criteria are met.

C. PRESSURE SUPPORT TRIAL DEFERRAL CRITERIA:

  • C6. High dose vasopressor requirements (i.e. epinephrine or norepinephrine >0.5ug/kg/min or equivalent) OR patient requiring an increase in dose of vasopressorwithin 6 hrs

  • C7. Active cardiac ischemia (dynamic ST changes on monitor or ECG within 6 hours)

  • C8. Unstable arrhythmias (HR>140 or <50) with clinical signs of low cardiac outputor or SBP<80 mmHg

  • C10. Receiving a "strict lung protective" ventilation strategy for ARDS (eg. Orderon chart to keep Vt ≤6 mL/kg PBW)

C. PRESSURE SUPPORT TRIAL EXCLUSION CRITERIA:

• C12. Treating physician has declined consent

D. WEANING CRITERIA:

  • D1. SpO2≥ 90% on FiO2 ≤0.40 and PEEP ≤8 cmH2O

  • D2. pH ≥7.32

  • D3. Vasopressor requirements no higher than norepinephrine 0.1 ug/kg/min orequivalent.

In the final stage (E), patients will be considered eligible for randomization if the following criteria are met.

E. RANDOMIZATION INCLUSION CRITERIA:

  • C1. Patient/SDM has provided consent OR Plan to obtain deferred consent as Patientincapable and no SDM available to provide consent within the randomization window

  • E1. Upon review of Criteria A, B, and C, the patient still passes and the patienthas passed the PST.

  • E2. Does not meet Weaning Criteria OR Fails the ZERO CPAP Trial OR Fails the SBT

E. RANDOMIZATION EXCLUSION CRITERIA:

  • B9. Patient has met enrolment inclusion criteria B1-B5 AND has tolerated pressuresupport of 0-20 cm H2O or proportional assist ventilation of 0-85% ≥24 consecutivehours (including time on CPAP, t-piece, or tracheostomy mask). Note (1): It isacceptable to include a patient who has been tried on pressure support orproportional assist ventilation but has required pressures >20 cmH2O or assistance >85% or has required return to A/C ventilation within the 24 hour time window; Note (2): B9 does not apply to patients while on ECMO

  • C4. Patient/SDM has declined consent

  • C5. Patient incapable and no SDM available to provide consent (not applicable ifplan to obtain deferred consent)

  • E3. Passed SBT on t-piece, FiO2 0.40 for 30-120 minutes

  • E4. Approval withdrawn (by physician or patient/SDM)

Study Design

Total Participants: 575
Treatment Group(s): 2
Primary Treatment: PAV+ ventilation strategy
Phase:
Study Start date:
September 14, 2016
Estimated Completion Date:
July 16, 2024

Study Description

Patients with acute respiratory failure require mechanical ventilation to help them breathe until they recover from their acute illness. Although mechanical ventilation is necessary to sustain life in such situations, it can induce weakness of the respiratory muscles which may lead to prolonged dependence on the ventilator. Prolonged dependence on mechanical ventilation is associated with increased mortality, morbidity and costs to the healthcare system. Thus, a main goal of assisted mechanical ventilation is to reduce the patient's respiratory distress while maintaining some respiratory muscle activity. To attain this goal, the amount of ventilator assistance should theoretically be adjusted to target normal or reasonable levels of respiratory effort.

Modes of Mechanical Ventilation:

Proportional assist ventilation with load-adjustable gain factors (PAV+) is a mode of mechanical ventilation which delivers assistance to breathe in proportion to the patient's effort. The proportional assistance, called the gain, can be adjusted by the clinician to maintain the patient's respiratory effort or workload within a reasonable range. This is the only mode of ventilation which allows for measurement and targeting of a specific range of respiratory muscle activity by the patient.

Pressure support ventilation (PSV) is a mode of ventilation which is considered the current standard of care for assisting breathing of patients during the recovery phase of acute respiratory failure. Several studies have shown short term advantages of PAV over PSV, including improved patient-ventilator synchronization, improved adaptability to changes in patient effort, and improved sleep quality.

Goal of this Randomized Controlled Trial:

To demonstrate that for patients with acute respiratory failure, ventilation with PAV+, being more physiological, will result in a shorter duration of time spent on mechanical ventilation than ventilation with PSV.

Connect with a study center

  • El Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"

    Buenos Aires, C1430EFA
    Argentina

    Site Not Available

  • Royal Columbian Hospital

    New Westminster, British Columbia
    Canada

    Site Not Available

  • Kingston General Hospital

    Kingston, Ontario
    Canada

    Site Not Available

  • London Health Sciences Centre - University Hospital

    London, Ontario N6A 5A5
    Canada

    Site Not Available

  • Victoria Hospital

    London, Ontario
    Canada

    Site Not Available

  • Mount Sinai Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • North York General Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • St. Michael's Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • Sunnybrook Hospital - Health Sciences Centre

    Toronto, Ontario M4N 3M5
    Canada

    Site Not Available

  • UHN- Toronto General Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • UHN- Toronto Western Hospital

    Toronto, Ontario
    Canada

    Site Not Available

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montréal, Quebec GC6R+GW
    Canada

    Site Not Available

  • Hôpital du Sacré-Cœur de Montréal

    Montréal, Quebec
    Canada

    Site Not Available

  • Royal Victoria Hospital

    Montréal, Quebec
    Canada

    Site Not Available

  • Institut Universitaire de cardiologie et de pneumologie de Quebec

    Québec, Quebec
    Canada

    Site Not Available

  • Centre Hospitalier Universitaire (CHU) de Angers

    Angers,
    France

    Site Not Available

  • Centre Hospitalier Intercommunal de Créteil

    Créteil, QFW8+H5
    France

    Site Not Available

  • Hôpital Henri Mondor (Assistance Publique-Hôpitaux de Paris)

    Créteil,
    France

    Site Not Available

  • Centre Hospitalier Universitaire (CHU) de Nice

    Nice,
    France

    Site Not Available

  • Hôpital Universitaire Pitié-Salpêtrière

    Paris,
    France

    Site Not Available

  • Centre Hospitalier Universitaire (CHU) de Rouen

    Rouen,
    France

    Site Not Available

  • University Hospital of Heraklion

    Heraklion,
    Greece

    Site Not Available

  • University Hospital of Ferrara

    Ferrara,
    Italy

    Site Not Available

  • San Giovanni Battista University Hospital

    Turin,
    Italy

    Site Not Available

  • King Abdulaziz Medical City

    Riyadh, 11426
    Saudi Arabia

    Site Not Available

  • Hospital de Sant Pau

    Barcelona,
    Spain

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.